Sep quarter: revenue down 38%, PAT loss of INR 775.4 million on exceptional charges
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended September 30, 2026: revenue from operations fell 38% to INR 560.5 million from INR 903.3 million a year earlier, and profit after tax was a loss of INR 775.4 million versus a profit of INR 242.2 million. Exceptional charges of INR 682.6 million cover a customer termination and invalid import licences. Half-year revenue was INR 1,598.6 million; borrowings of INR 7,960.1 million exceed equity of INR 7,717.2 million.
Revenue loss, a large one-off charge and borrowings above equity likely pressure the stock; a planned rights issue may dilute shareholders.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.